<DOC>
	<DOCNO>NCT02184624</DOCNO>
	<brief_summary>This randomise , open-label , placebo , crossover , multicentre study single visit . The study comprise five sub-studies . Subjects receive inactive treatment ( placebo ) via ELLIPTA® inhaler one inhaler device depend sub-study randomise . Only subject naïve ELLIPTA inhaler one inhaler device use study include . Furthermore , subject naïve BREEZEHALER® HANDIHALER® inhaler must naïve inhaler device require capsule . The study conduct UK Netherlands , comprise one visit . A sufficient number subject ( least 600 ) COPD screen 570 randomise one five sub-studies . Eligible subject allocate one sub-studies depend experience use inhaler ( i.e. , depend inhaler naïve ) . This study design assess proportion COPD subject make critical overall ( i.e. , critical non-critical error ) error use ELLIPTA inhaler commercially available inhaler device TURBUHALER® , HANDIHALER , BREEZHALER , MDI DISKUS®/ACCUHALER® inhaler . This study also assess 'ease use ' preference ELLIPTA inhaler commercially available inhaler device . ELLIPTA , DISKUS , ACCUHALER register trademark GSK group company . TURBUHALER register trademark AstraZeneca . HANDIHALER register trademark Boehringer Ingelheim Pharma GmbH &amp; Co. KG . BREEZHALER register trademark Novartis AG .</brief_summary>
	<brief_title>Study Inhaler Device Attributes Investigating Critical Overall Errors , Ease Use , Preference Between Number Inhaler Devices</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Informed consent : Subject must give sign dated write informed consent participate study ; Subject understand willing , able , likely comply study procedure restriction ; Subject must able read , comprehend , record information Dutch and/or English . Age : &gt; =40 year age Gender : Male female subject . Primary diagnosis COPD : subject clinical history COPD accordance definition American Thoracic Society/European Respiratory Society . Comorbidities ( rheumatoid arthritis locomotor problem , visual impairment , depression anxiety ) document relevant inhaler use . COPD treatment : All patient currently receive treatment COPD . Must naïve use ELLIPTA inhaler least one inhaler device . Subjects naïve BREEZEHALER HANDIHALER inhaler must naïve inhaler device require capsule . Asthma : Subjects current diagnosis asthma . Note : Subjects prior history asthma eligible current diagnosis COPD . Contraindications : A history allergy hypersensitivity lactose/milk protein magnesium stearate excipient . Subjects currently participate another randomised pharmacological interventional trial . Inability Read : In opinion investigator , subject unable read and/or would able complete questionnaire understand verbal instruction .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>BREEZHALER</keyword>
	<keyword>DISKUS/ACCUHALER</keyword>
	<keyword>MDI</keyword>
	<keyword>Inhaler preference</keyword>
	<keyword>Overall inhaler error</keyword>
	<keyword>HANDIHALER</keyword>
	<keyword>Ease use</keyword>
	<keyword>TURBUHALER</keyword>
	<keyword>ELLIPTA</keyword>
	<keyword>Critical inhaler error</keyword>
</DOC>